NCT02795858: A trial that was reported late by Dana-Farber Cancer Institute
This trial has reported, although it was 3 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02795858 |
|---|---|
| Title | A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | June 14, 2016 |
| Completion date | Dec. 31, 2022 |
| Required reporting date | Dec. 31, 2023, midnight |
| Actual reporting date | Jan. 3, 2024 |
| Date last checked at ClinicalTrials.gov | Feb. 9, 2024 |
| Days late | 3 |